Ask AI
Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies
Interactive Case Challenges: Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies

Released: April 30, 2025

Activity

Progress
1
Course Completed

Case History and Presentation  
Jeremy, a 39-year-old man, presents with refractory moderate to severe AD. His condition has persisted despite consistent use of topical corticosteroids, emollients, and intermittent systemic corticosteroids for severe flares. Jeremy reports intense itching, widespread lesions, and significant emotional distress caused by his symptoms. He rates his quality of life as “poor” and notes frustration with his current regimen. 

Jeremy’s dermatologist discusses the possibility of advanced biologic therapy targeting IL-13. She reviews current guideline recommendations and shares key evidence supporting the use of these therapies and other therapies for AD. 

Patient History: 

  • Eczema Area and Severity Index (EASI) score: 29
  • Body surface area involvement: 20% 
  • Patient-reported Pruritus Numeric Rating Scale (NRS): 8/10 
  • No significant comorbid conditions or contraindications to biologic therapies 

Jeremy is frustrated by the lack of sustained control with systemic corticosteroids. Which advanced therapy targeting IL-13 is most appropriate to initiate based on current evidence?